Nok Therapeutics, Inc.
Raising nowOperatingBiotech · Ormond Beach, FL
Nok Therapeutics develops cancer treatments built from a patient's own Natural Killer (NK) immune cells, aimed at blood cancers and solid tumors. Its lead candidate, evancaleucel, has completed a Phase I trial in multiple myeloma; its other candidates are preclinical.
This company has an open fundraising round.
Financials
FY2023–FY2025 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inDotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.
Share price over rounds
Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.
Cap table
Share counts as of Dec 31, 2025These classes don't convert into each other and last sold at very different prices, so their share counts can't be added up into ownership percentages. Compare them by price instead.
| Class | Outstanding | Votes / share | Last price |
|---|---|---|---|
| common stock | 46,968,550 | — | $0.0575Sep 2024 |
| Class A Common(as of Dec 23, 2024) | 30,775,500 | 1 | $2.00Jan 2025 |
Principal holders% as the filing states it, Apr 30, 2026
- Marlew, LTD.8,905,121 common stock19.0%of company
- NCF Charitable Assets Trust, NCF Giving INC, TTEE6,020,750 common stock12.8%of company
- Robert Lewis5,800,000 common stock12.3%of company
- Eagle Investment Group4,350,000 common stock9.26%of company
- MedTek, LLC1,632,500 common stock3.48%of company
- Brian Cogley447,200 common stock0.95%of company
- Tamara Jovonovich430,000 common stock0.92%of company
- Everyone else (not named in filings)41.3%
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
4 peopleNames and titles as disclosed on SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.
SEC filings
View all 22 filings on EDGAR- Form 1-SASep 28, 20260001213900-26-103889EDGAR
- Form 1-UJul 15, 20260001213900-26-078262EDGAR
- Form 1-UJun 3, 20260001213900-26-064632EDGAR
- Form D/AMay 1, 20260001213900-26-050994EDGAR
- Form D/AMay 1, 20260001213900-26-050987EDGAR
- Form 1-KApr 30, 20260001213900-26-050128EDGAR
- Form D/AApr 22, 20260001213900-26-046538EDGAR
- Form D/AApr 22, 20260001213900-26-046528EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.